Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal mixed signals. While the company has promising programs and a solid cash runway until 2027, the lack of concrete partnership updates and unproven scalability of the AI-Immunology platform pose risks. The financial performance is stable, but not exceptional, with a net loss in line with expectations. The operational changes and strategic focuses are promising but yet to show results. Given these factors, the stock is likely to remain stable over the next two weeks, resulting in a neutral rating.
Key Financial Performance
Operating Expenses Operating expenses overall more or less in line with last year, but slightly reduced. R&D expenses saw a minor increase due to the progression of the pipeline and programs, while G&A expenses were slightly lower, mainly driven by reduced capital market costs in Q1 '26 versus the same period in '25.
Net Loss The first quarter resulted in a net loss of USD 3.6 million, which is in line with the company's plan.
Cash Position Cash position and equivalents at the end of the quarter stood at $18.4 million, confirming a cash runway until the second half of 2027.
Total Equity Total equity reduced to USD 13.2 million at the end of the quarter, primarily due to the net loss incurred during the first quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EVX-01 Phase II Study: Reported 86% immunogenicity conversion rate and 86% de novo T-cell response rate, indicating strong immune activation and clinical benefit.
AI-Immunology Platform: Demonstrated scalability to glioblastoma and other cancers, showcasing broader applicability.
Polio Vaccine Concept: Presented a new concept in collaboration with The Gates Foundation, highlighting potential for improved vaccine design.
Business Development and Partnering: Strengthened external outreach and positioning to raise awareness of Evaxion's products and platform, with ongoing discussions for partnerships.
Organizational Reorganization: Promoted Birgitte Rono to CSO and COO to enhance operational focus and external engagement.
Resource Allocation: Maintained disciplined resource allocation, with an operational cash burn of $14 million projected for 2026 and a cash runway into the second half of 2027.
Pipeline Development: Focused on advancing oncology and infectious disease programs, including EVX-01, EVX-03, and preclinical assets like EVX-04 and EVX-B1.
Partnership Strategy: Driving partnerships to leverage platform and assets for early development and value creation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Business Development and Partnering: The company is focusing on external outreach and positioning to raise awareness and develop partnerships. However, there is no concrete update on finalized partnerships, which could pose a risk to achieving strategic objectives.
R&D and AI-Immunology Platform: While the company has shown promising data in oncology and infectious diseases, the scalability and broader applicability of the AI-Immunology platform remain unproven in clinical settings beyond melanoma. This could impact future development and commercialization.
Financial Sustainability: The company has a cash runway until the second half of 2027, but this assumes no additional partnerships or deals. Failure to secure these could lead to financial constraints.
Regulatory and Clinical Development: The EVX-01 program has received FDA Fast Track designation, but further trials and approvals are required. Delays or failures in clinical trials could hinder progress and commercialization.
Operational Changes: The reorganization and promotion of key personnel aim to enhance focus on strategy and external engagement. However, the effectiveness of these changes in achieving strategic goals is yet to be demonstrated.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Business Development and Partnerships: The company is focusing on external outreach and positioning to raise awareness of its products and platform. Discussions are ongoing, with updates expected later in the year.
R&D and AI-Immunology Platform: The company plans to update on the broader applicability of its AI-Immunology platform in glioblastoma and autoimmune diseases later in the year. Initial data on a new polio vaccine concept has been presented, with further updates expected.
EVX-01 Program: The company will announce 3-year data, including clinical outcomes, in the second half of 2026. Additional cancer indications are being evaluated, with further trials expected in partnership. The program has received FDA Fast Track designation.
EVX-04 Program: The off-the-shelf vaccine program targeting AML is aiming for clinical readiness by the end of 2026.
Infectious Diseases Programs: Preclinical assets, including EVX-B1 (Staph aureus), EVX-B2 (Neisseria gonorrhea), and EVX-B3 (Group A Streptococcus), are progressing. Updates on these programs are expected as they mature.
Financial Guidance: The company expects an operational cash burn of approximately USD 14 million for 2026, with a cash runway extending into the second half of 2027. This projection does not assume any new partnerships or deals.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Will the 3-year EVX-01 data be presented at a scientific meeting like ESMO or independently?
A:The data will be updated in the context of a scientific meeting, not independently. The specific conference will be confirmed once abstracts are released.
Q:What is the strategic intent for the GBM data? Will it be taken into humans or partnered?
A:The company anticipates partnering for the GBM data, as it strengthens their personalized approach with EVX-01. Further updates will depend on additional data and discussions.
Q:What is the design philosophy and strategy for expanding indications in cancer, particularly for diseases where PD-1s have been ineffective?
A:The company focuses on understanding antigenic landscapes and designing high-quality vaccines for various indications. They are exploring over 30 indications and aim to fit therapies to antigen profiles, not necessarily limited to PD-1 low patients.
Q:Does the company prefer developing universal vaccines for multiple tumor types or individual vaccines for specific tumors?
A:The approach depends on the antigenic landscape. If conserved antigens are found across patients, they prefer off-the-shelf vaccines for simplicity and cost-effectiveness. For indications with diverse profiles, personalized vaccines are considered.
Q:Can you provide more details on the ongoing partnership discussions? Are they leaning towards broad platform licensing or specific asset-based collaborations?
A:The company cannot provide detailed information at this point. They are prioritizing partnerships for EVX-01 and exploring broader applicability beyond melanoma. Discussions also include assets in the infectious diseases portfolio, with a strategic focus on maximizing value.
Q:When can we expect more details on the autoimmune platform?
A:More details are expected in the second half of the year, aligned with relevant scientific conferences.
Q:Review of Unclear Management Responses
A:The management avoided providing specific details on the ongoing partnership discussions, stating they cannot say much at this point. They used vague language and did not disclose whether discussions are leaning towards broad platform licensing or specific asset-based collaborations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AACR
AI Immunology
AML
CSO COO
Duke University
EVX program
EVX vaccine
GBM
Head
IRF
Immunology platform
Immunology vaccine
Phase II
Slide
allocation
applicability
brain
burden tumor
collaboration
concept disease
correlation
design
focus area
immunogenicity
novo cell
outreach
plan
platform glioblastoma
polio vaccine
portfolio
potential
product
program Group
program Phase
resource
response benefit
term
vaccine concept
EVAX Transcript
Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary and Q&A reveal mixed signals. While the company has promising programs and a solid cash runway until 2027, the lack of concrete partnership updates and unproven scalability of the AI-Immunology platform pose risks. The financial performance is stable, but not exceptional, with a net loss in line with expectations. The operational changes and strategic focuses are promising but yet to show results. Given these factors, the stock is likely to remain stable over the next two weeks, resulting in a neutral rating.
Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript
Positive3-6
The earnings call summary and Q&A indicate a positive outlook for Evaxion. The financial performance shows improved revenue and reduced operational costs, leading to a better financial position. The extended cash runway and strengthened equity are positive indicators. Product development, particularly the progress of EVX-01 and potential of EVX-04, is promising. The AI-Immunology platform enhancements and ongoing partnerships add further optimism. Despite some uncertainties in responses, the overall sentiment is positive, suggesting a likely stock price increase in the short term.
Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights positive financial performance with a cash runway extended to 2027 and revenue from MSD. Significant progress in R&D, particularly in oncology and infectious diseases, enhances the company's growth prospects. While there are potential risks in partnerships and production, the overall sentiment is positive, supported by optimistic guidance and ongoing partnership discussions. The Q&A section reveals strong interest in the company's pipeline and technology, further boosting confidence. Despite some uncertainties, the overall outlook is positive, suggesting a potential stock price increase of 2% to 8%.
Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript
Unknown8-19
The earnings call presents a mixed outlook. Positive aspects include a solid cash position and business development pipeline, along with reduced losses. However, challenging financial markets, increased regulatory uncertainty, and dependency on partnerships pose significant risks. The Q&A session highlighted management's avoidance of specifics, adding uncertainty. Overall, the potential for partnerships and the Merck collaboration are positive, but the risks and uncertainties balance out, leading to a neutral sentiment.
EVAX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
